Concepedia

Anna V. Kovyrshina

AV

Statistics

Publications

10

Citations

3.2K

H-Index

10

Active since

2020

Affiliations

Ministry of Health of the Russian Federation(Current)

Sechenov University

27th Central Research Institute of the Ministry of Defence of the Russian Federation

Research Institute of Influenza

Peoples' Friendship University of Russia

Anna V. Kovyrshina is an author at Ministry of Health of the Russian Federation specializing in immunology, medicine, and covid-19.

ORCID

Top concepts

Publications per year

2020–2023

10

Publications

10

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov et al. · The Lancet · 2021 · 1.8K citations · Full text

, , +10

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov, Inna V. Dolzhikova, Olga V. Zubkova et al. · The Lancet · 2020 · 1.1K citations · Full text

, , +7

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Vladimir А. Gushchin, Inna V. Dolzhikova, Andrei E. Siniavin et al. · Vaccines · 2021 · 118 citations · Full text

, , +18

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults

Amir I. Tukhvatulin, Inna V. Dolzhikova, Dmitry V. Shcheblyakov et al. · The Lancet Regional Health - Europe · 2021 · 71 citations · Full text

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern

I. A. FAVORSKAYA, Dmitry V. Shcheblyakov, I. B. Esmagambetov et al. · Frontiers in Immunology · 2022 · 35 citations · Full text

, , +12

1–5 of 10